Phenotypes Associated with This Genotype

Genotype
MGI:5317170

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Scgb1a1^{tm1(cre/ERT)Blh}/Scgb1a1⁺; Trp53^tm5Tyj/Trp53⁺
• Genetic Background: involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased tumor-free survival time ( J:182218 )

• animal succumb due to tumor burden at 20-24 weeks

neoplasm

increased lung adenoma incidence ( J:182218 )

• at 6-8 weeks of age, animals administered 4 doses of tamoxifen develop adenomas in the alveoli by 15 weeks; these progress to adenocarcinomas

• papillary adenomas are seen in alveoli at 15 and 21 weeks after tamoxifen treatment

increased adenocarcinoma incidence ( J:182218 )

• develop in alveoli and near the bronchioalveolar duct junction by 15 weeks of age with tamoxifen administration at 6-8 weeks

• larger bronchioles and non terminal bronchi appear normal

• advanced papillary adenocarcinomas are observed at 21 weeks after tamoxifen treatment

respiratory system

increased lung adenoma incidence ( J:182218 )

• at 6-8 weeks of age, animals administered 4 doses of tamoxifen develop adenomas in the alveoli by 15 weeks; these progress to adenocarcinomas

• papillary adenomas are seen in alveoli at 15 and 21 weeks after tamoxifen treatment

abnormal bronchoalveolar duct junction morphology ( J:182218 )

• hyperplasia is observed at 3 weeks after tamoxifen induction, and persists at 15 and 21 weeks